CAU
DFTX

Caxton Associates (UK)’s Definium Therapeutics DFTX Stock Holding History

Caxton Associates (UK)’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-37,255
Closed -$704K – 893
2026
Q1 		$704K Buy
37,255
+21,564
+137% +$366K 0.02% 450
2025
Q4 		$210K Buy
15,691
+5,046
+47% +$62.4K ﹤0.01% 702
2025
Q3 		$126K Buy
+10,645
New +$99.3K ﹤0.01% 661

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Caxton Associates (UK)'s DFTX Position: Q2 2026 in Review

Caxton Associates (UK) sold out of Definium Therapeutics (DFTX) in Q2 2026, closing a stake of 37,255 shares — an estimated $704K sold.

Caxton Associates (UK) first reported a position in DFTX in Q3 2025 and held it in 3 quarters. The position peaked at $704K in Q1 2026. 362 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • Caxton Associates (UK) reported no remaining Definium Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Caxton Associates (UK) sold 37,255 Definium Therapeutics shares in Q2 2026, an estimated $704K.
  • Caxton Associates (UK) first reported a position in Definium Therapeutics in Q3 2025 and held it in 3 quarters.
  • Caxton Associates (UK)'s Definium Therapeutics position peaked at $704K in Q1 2026.
  • 362 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Caxton Associates (UK)'s 13F filing for Q2 2026, filed 14 Aug 2026.